Nova Biomedical expands its cell line development platform by acquiring NanoCellect's microfluidic cell sorting assets
Executive summary: Nova Biomedical acquired certain assets of NanoCellect, integrating the company's microfluidic cell sorting technology into its own portfolio. The acquisition enhances Nova's integrated cell line development offerings, strengthening its position in the rapidly expanding cell therapy manufacturing market.
Who is involved: Nova Biomedical (buyer) and NanoCellect (seller), both based in the Waltham, Massachusetts area.
Likely next: Integration of NanoCellect sorters into Nova's workflow, with a joint product launch expected by early 2027 and financial terms likely disclosed in Nova's Q3 2026 earnings call.
Nova Biomedical has acquired select microfluidic cell sorter assets from NanoCellect, a move that adds NanoCellect’s flagship sorting instruments to Nova’s existing cell line development platform. The acquisition expands Nova’s product portfolio to include a key step—single‑cell sorting—alongside its current reagents, instruments and software, thereby enabling a more contiguous workflow for customers developing therapeutic cell lines. This development is relevant because the cell therapy manufacturing market is expanding rapidly, prompting biopharma companies and contract manufacturers to seek end‑to‑end solutions that reduce hands‑on time, improve reproducibility and accelerate timelines. By integrating sorting capabilities into its suite, Nova can address a growing demand for streamlined, unified workflows that minimize the need to juggle multiple vendors. The transaction also reflects a broader pattern of consolidation among suppliers of single‑cell analysis tools, as larger players seek to offer broader, more integrated portfolios. In the near term, Nova is expected to emphasize the combined sorting and cell line development capabilities in its communications with existing and prospective clients. While financial terms of the deal have not been disclosed, the addition of NanoCellect’s assets broadens Nova’s addressable market within the fast‑growing cell therapy sector and positions it to compete more effectively against other providers offering fragmented versus integrated solutions.
Timeline
- — Nova Biomedical fait progresser les processus intégrés de développement de lignées cellulaires : les produits de NanoCellect entrent dans la gamme de Nova Biomedical (PR Newswire)
- — Nova Biomedical Advances Integrated Cell Line Development Workflows: NanoCellect products are now part of Nova Biomedical (PR Newswire)
Analysis — what this means
Likely next events
- Integration of NanoCellect sorters into Nova Biomedical's workflow expected by Q4 2026.
- Joint product launch planned for early 2027 targeting cell therapy manufacturers.
- Nova Biomedical to disclose financial terms of the asset purchase in its Q3 2026 earnings call scheduled for October 2026.
Sectors affected
- Cell line development
- Microfluidic cell sorting
- Biopharmaceutical manufacturing
Historical parallels
- Beckman Coulter's acquisition of Apogee Flow Systems in 2019 added microfluidic sorting capabilities to its portfolio.
Key entities
Sources
- Nova Biomedical fait progresser les processus intégrés de développement de lignées cellulaires : les produits de NanoCellect entrent dans la gamme de Nova Biomedical — PR Newswire
- Nova Biomedical Advances Integrated Cell Line Development Workflows: NanoCellect products are now part of Nova Biomedical — PR Newswire
Related cases
- Nova Biomedical acquires NanoCellect assets to boost its cell line development capabilities
- Nova Biomedical integrates NanoCellect's microfluidic cell sorting technology to expand cell line development workflows
- Nova Biomedical bolsters its cell line development platform by integrating NanoCellect’s microfluidic cell sorting assets